Illumina Inc. (NASDAQ:ILMN) was upgraded by Vetr from a “sell” rating to a “buy” rating in a report issued on Monday. The firm currently has a $198.61 target price on the life sciences company’s stock. Vetr‘s target price points to a potential upside of 8.99% from the stock’s previous close.

Other research analysts also recently issued reports about the stock. CL King started coverage on shares of Illumina in a report on Tuesday, June 21st. They set a “buy” rating and a $165.00 price target for the company. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 price target for the company in a report on Friday, August 26th. Argus upped their price target on shares of Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, August 8th. Citigroup Inc. upped their price target on shares of Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, September 12th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $165.00 price target on shares of Illumina in a report on Wednesday, July 27th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Illumina has an average rating of “Hold” and an average target price of $164.94.

Illumina (NASDAQ:ILMN) traded up 0.31% during midday trading on Monday, reaching $182.23. The company had a trading volume of 1,101,885 shares. The company has a market capitalization of $26.71 billion, a PE ratio of 62.41 and a beta of 0.47. Illumina has a one year low of $127.10 and a one year high of $196.47. The stock’s 50 day moving average is $173.13 and its 200 day moving average is $155.45.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.13. The company earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.80 earnings per share. Equities research analysts forecast that Illumina will post $3.53 earnings per share for the current fiscal year.

In related news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $172.99, for a total value of $3,459,800.00. Following the sale, the director now owns 508,061 shares in the company, valued at approximately $87,889,472.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert S. Epstein sold 300 shares of the company’s stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total transaction of $52,287.00. Following the completion of the sale, the director now owns 6,924 shares in the company, valued at approximately $1,206,783.96. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of ILMN. BlackRock Japan Co. Ltd raised its stake in Illumina by 1.7% in the first quarter. BlackRock Japan Co. Ltd now owns 181,033 shares of the life sciences company’s stock worth $29,347,000 after buying an additional 3,001 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Illumina by 2.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,791,848 shares of the life sciences company’s stock valued at $614,696,000 after buying an additional 94,558 shares during the period. BlackRock Group LTD raised its stake in Illumina by 4.5% in the first quarter. BlackRock Group LTD now owns 1,133,781 shares of the life sciences company’s stock valued at $183,797,000 after buying an additional 48,818 shares during the period. BlackRock Inc. raised its stake in Illumina by 2.6% in the first quarter. BlackRock Inc. now owns 354,614 shares of the life sciences company’s stock valued at $57,486,000 after buying an additional 8,869 shares during the period. Finally, Prudential Financial Inc. raised its stake in Illumina by 0.7% in the first quarter. Prudential Financial Inc. now owns 179,455 shares of the life sciences company’s stock valued at $29,092,000 after buying an additional 1,300 shares during the period. Institutional investors own 95.22% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.